Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

NRIX - Nurix Therapeutics, Inc. Последние новости | Finranks

Home

/

NRIX

N

Nurix Therapeutics, Inc. (NRIX)

NGM – Цена в реальном времени. Валюта: USD

15.96

-0.32 (-1.97%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix's scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?

Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies.

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $0.67 per share a year ago.

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

Видео

No Data

There is no data to display

Пресс-релизы

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix's scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California.